The Jerusalem PostAustralia sanctions individuals, organizations tied to West Bank settlements, settler violenceInquirerOas in Albay launches digital services to cut red tape, lessen feesPunchFG orders recovery of excess payments to university workersCNN TürkRESMİ GAZETE KARARLARI 18 KASIM: Resmi Gazete atamaları ve kararları neler? Bayburt Üniversitesi öğretim üyesi alımı ilanı yayınlandı!한겨레미국 노동자, 업무에 AI 사용시간 5.3% 불과…“AI 생산성효과 아직 미미”ZDF heuteAktuelle Pressemitteilungen des ZDFNew Straits TimesPolice arrest 36 foreigners in Kuantan love scam raids경향신문46표 차로 당선된 전화식 성주군수···경찰, ‘위장전입 의혹’ 압수수색GMA NewsSara Duterte camp says 2 former staff now safe amid alleged threatsDeadlineIDA Awards Nominations: ‘Concrete Land’ Lands 6, With ‘To Hold A Mountain’ Close Behind; Elizabeth Holmes Doc In The MixХабр«Процесс» Франц КафкаLa NaciónVideo: los golazos de Nico Paz, Julián Álvarez, Franco Mastantuono y Alexis Mac Allister para la Argentina ante Costa Rica
The Daily Newsstand · Free, Always
Wednesday, November 18, 2026

White House drops Heidi Overton’s FDA nomination after Republicans raise concerns

Translate

WASHINGTON — The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday.

The decision comes a day before the Senate Health Committee was scheduled to vote on whether to advance her nomination to the full Senate for confirmation.

Axios first reported the White House’s decision.

The move follows weeks of doubts from key Republicans on Health, Education, Pensions and Labor Committee.

Sen. Bill Cassidy of Louisiana, the committee’s chairman, questioned whether Overton — a preventive medicine doctor who serves as a domestic policy official in the White House — had enough experience to lead the agency. Prior to joining the White House, Overton worked as chief policy officer at the conservative think tank America First Policy Institute.

Sen. Susan Collins, R-Maine, told NBC News last week that she was undecided and had “not taken a position,” saying she needed “to get some answers on various things.”

Overton has praised the Supreme Court’s decision to overturn Roe v. Wade and called for strict restrictions on medication abortion.

The FDA is set to finish its safety review of mifepristone in March, one of the most consequential decisions the agency faces.

Overton’s nomination was already working against a tight window. Democrats take control of the Senate in January, when she would have to be renominated, and her chances of being confirmed then would be slim.

The FDA has been without a permanent commissioner since Dr. Marty Makary resigned in May, in part because of the administration’s decision to authorize several fruit-flavored vaping products.

The vacancy adds to a long period of upheaval at the nation’s top health agencies. The Centers for Disease Control and Prevention went nearly a year without a permanent director after Health Secretary Robert F. Kennedy Jr. removed Susan Monarez just 29 days into the job last year. Trump’s first pick for that role, former congressman Dave Weldon, couldn’t secure enough Republican support, and the agency cycled through a series of acting leaders before the Senate confirmed Dr. Erica Schwartz in August.

View the original on NBC News →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.